Dr. Darryl See -- Study Of Effectiveness of Transfer Factor

 

TRANSFER FACTOR (Improves Immune System) "Transfer factor is a highly concentrated immune messaging system, designed by nature to transfer critical immune programming from one individual to another." William J. Hennen, Ph.D. Biochemist   Independent Study Results 4Life Transfer Factor™ & Transfer Factor Plus™ "Unprecedented" Immune Boosting Ability . Recently we reported the initial results of a groundbreaking independent study using 4Life Transfer Factor™ and Transfer Factor Plus™. Both yielded unprecedented results in a study done by the Institute of Longevity Medicine in California, a laboratory recognized for its research and expertise in measuring the ability of ingredients to significantly boost the immune system.   4Life Transfer Factor™ and Transfer Factor Plus™  were tested for their ability to increase Natural Killer Cell (NK) activity by killing live cancer cells. The research used peripheral blood mononuclear cells (PBMC) isolated from human volunteers. Test results showed that 4Life Transfer Factor™ increased the NK cell activity 103% above immune response without supplementation, more than two times higher than the next highest product. The study also showed . that Transfer Factor Plus™ increase the NK cell Activity 248% above normal immune response without supplementation, or about five times higher than any of the other previously tested products.    Natural Killer Cells are an important part of our body's defense against infection and sickness. They seek and destroy infected or malignant cells and cells infected by viruses (colds/flu's).    David Lisonbee, President of 4Life Research™, in response to this research said, "These recent findings support and substantiate the reports form thousands of distributors who use Transfer Factor™ and Transfer Factor Plus™. The study also supports many other clinical experiences and studies we are familiar with. We are very pleased with the study results—they come as no surprise to us"

 

 

Noni (Morinda citrafolia)  15% Aloe vera    Concentrate  (acemannan) 15% Endocine System Formula 16% Phytontrient Formula with Garlic 21% Bovine Colostrum 23% Cordyceps Formula 28% Shiitake Mushroom 42% Echinacea Plant 43% Poly- saccharide Formula 48% IP6 (highestof group previously tested) 49% 4Life Transfer Factor™ 104% 4Life Transfer Factor Plus™ 248% 5 times better than the best product tested

JEUNESSE Inc.  Institute of Longevity Medicine   PRELIMINARY REPOT (additional test results to follow)  Transfer factor testing 11-5-99    Background and rationale: 1) Cancer is the second leading cause of death in the US. The rate of nearly every type of cancer is on the rise. Despite billions of dollars in research, the mortality rate has remained nearly unchanged since the 1960's using conventional treatments such as radiation, surgery and chemotherapy. Thus, there is considerable interest in using immune modulation as an adjuvant for cancer therapy. Natural killer cells are particularly important in destroying cancer cells.    Purpose of study: 1) To determine the in vitro anti-cancer effects of Transfer Factor and Transfer Factor Plus using PBMC isolated from human volunteers and assaying the increased ability of the NK cell population to kill K562 erythroleukemic cells.    Methods: 1) PBMC killing of K 562 (erythroleukemic) cells      Results 1) Transfer Factor increased NK-cell killing by 100%  and Transfer Factor Plus by 250%   Conclusions: Transfer Factor and Transfer Factor Plus induced immune based lysis of K562 cells at a level unprecedented in the director's experience or in the known medical literature. Since NK cell function is so crucial in killing cancer cells, these products are ideal candidates for cancer adjuvant therapy. In addition, NK cells form a first line of defense against infections from viruses and certain other microorganisms. Killing assays against K562 cells have also been correlated with increased with increased activity against chronic and acute infections as well.    Darryl See MD Director, Bioassay Laboratory Institute of Longevity Medicine http://www.emmessar.com/colostrum/0/A/Research/p4.htm

 

CancerOption.com Appoints Dr. Darryl See, M.D. As Chief Medical Officer And Director To The Company's Board Of Directors Market Wire,  January, 2000   CancerOption.com, Inc. (Symbol: CAOP), an innovative cancer specific health care portal, announced today the appointment of Dr. Darryl See, M.D. to the Company's Board of Directors as the Chief Medical Officer. Dr. See is currently a member of the CancerOption.com Scientific Advisory Board and the Co-Director of the EPD Cancer Clinic in Huntington Beach, California, which is celebrating enormous success since its recent grand opening. To review Dr. Darryl See's Curriculum Vitae and credentials please visit: http://www.canceroption.com/drsee/curriculumvitae Dr. See's responsibilities as CancerOption.com's Chief Medical Officer will include providing proprietary content and hosting "Ask the Cancer Specialist," an upcoming feature on the portal. According to statistics provided by the American Cancer Society, since 1990, approximately 12 million new cancer cases have been diagnosed and in the United States, men have a 1 in 2 lifetime risk of developing cancer, and women have a lifetime risk of 1 in 3. This new component will allow millions of cancer patients and family members to anonymously submit questions regarding cancer and the immune system while receiving timely answers in an open forum. According to Cyber Dialogue, a leading Internet database-marketing company, 50% of all online users would be interested in using a web site operated by their own doctor's office, but only 4% of doctor's offices currently offer web sites. The new "Ask the Cancer Specialist" feature at CancerOption.com will provide those individuals whose family doctor or oncologist does not offer a web site or e-mail a forum to have their inquiries addressed by a qualified medical professional. This new component will be available on the CancerOption.com portal prior to the official public launch. Clinical Studies To Be Conducted Furthermore, as a participating Board member for CancerOption.com, Dr. See will conduct clinical studies on selected proprietary nutraceuticals within a state of the art, doctor-managed laboratory. These clinical studies will implement the most current, scientifically validated testing methods on nutritional supplements including the ability to boost natural killer cell function, protect normal cells from cancer; induce apoptosis (cell suicide) in cancer cells and induce oxidative stress in cancer cells. Arnold Takemoto, President and Chief Executive Officer of CancerOption.com states, "Since Dr. Darryl See's appointment in November to the Company's Scientific Advisory Board, his level of commitment, participation and professionalism including his impressive credentials, certainly warrants this promotion to Chief Medical Officer and to the CancerOption.com Board of Directors." Mr. Takemoto continues, "The clinical studies conducted by Dr. See will not only distinguish CancerOption.com from other online health care web sites by providing proprietary, cancer related research but also enhance the credibility of the complementary protocol therapies available at the CancerOption.com portal. Dr. See is committed to providing reliable, credible and proven results to the public and over the past six years, he has been awarded numerous research grants and contracts totaling in excess of $1.6 million." CancerOption.com's mission is to provide a clear and concise informational stream of content in an effort to educate the general public and physicians on a variety of methods to enhance the immune system as it relates to cancer. Within the CancerOption.com virtual community, forums discussing the latest research findings, clinical trials, traditional and alternative therapies as well as professional forums with oncologists, physicians and healthcare professionals will be available worldwide. The protocols and targeted nutraceuticals, within the CancerOption.com portal, work in conjunction with current traditional cancer therapies. Return to Investor Relations For more information, please visit our web site at www.canceroption.com Disclaimer: Statements, which are not historical facts, are forward-looking statements. The Company, through its management makes forward-looking public statements concerning its expected future operations, performance and other developments. Such forward-looking statements are necessarily estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors, factors which could cause actual results to differ materially from those estimated by the Company include, but not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company's public announcements.  http://findarticles.com/p/articles/mi_pwwi/is_200001/ai_mark03990706

Dr. Darryl See’s Treatment for Chronic Fatigue Syndrome (CFS) by Janet Mizrahi October 17, 2000 Darryl See, M.D., an immunologist who practices in Huntington Beach, California, believes that there is no one single cause for Chronic Fatigue Syndrome, but also believes that it can be successfully treated. He and his associates at the Immune Institute attack CFS on two main fronts: treating both nutritional deficiencies and bacterial infections. Dr. See emphatically believes “that science has shown us that CFS is definitely an illness and not a psychological problem. Many patients are diagnosed with depression when there’s really something organically wrong with them.” He adds that it is important to understand that there is no magic or standardized protocol for CFS, that every patient is different, but that certain likenesses seem to be present in those with the condition. Nutritional Supplements “The body can heal itself with the right nutrients,” says Dr. See, and those very nutrients seem to be deficient in patients with CFS. In fact, he says, “All patients we’ve looked at in our practice are deficient in amino acids, vitamins and minerals, and a component called glyconutrients.” Compounding to or causing the nutritional deficiencies, Dr. See adds, is Leaky Gut Syndrome, a condition whereby the body cannot absorb certain nutrients from the GI tract. When examining patients, Dr. See looks for this malabsorption. If there is no apparent reason for it, the first part of treatment involves replacing the nutrients through supplementation. In patients with severe malabsorption, intravenous supplementation becomes necessary. This way the nutrients bypass the gut and go directly to the blood. But Dr. See and his associates prefer administering supplements orally. They test to see which amino acids, minerals and vitamins each patient is deficient in and replace them. One of these is frequently a substance called glyconutrients. Simply put, they are basic sugars, not like those in table sugar or fruit, but sugars necessary for normal cellular structure function and metabolism. About 85% of all structures in cells are glycoproteins. Although people generally get enough protein from their diets, they do not get the glyconutritionals. People with deficient glyconutrient levels are exhausted because cells are not structurally correct. Enzymes drive all cellular metabolic functions and require fuel to act. Enzymes use essential saccarides--glyconutritionals--as this fuel. In people with deficient glyconutritional levels, the result is poor immune system function and poor cognitive function, among other symptoms. Replacing this deficiency results in great improvement, according to Dr. See. Bacterial Treatment The second area of CFS treatment involves treatment of micoplasma incognitus. “In studies we’ve done at the Institute of Molecular Medicine, 70% of CFS patients are superinfected with micoplasma incognitus,” he comments. This bacteria is not to be mistaken for micoplasma pneumoniae, he cautions. It is a species of micoplasma called micoplasma fermentans. Most physicians will not test for this specific species unless they are sophisticated and knowledgeable about CFS. If tested for the pneumoniae, most people with CFS will test negative, and the problem will have been overlooked. Micoplasma incognitus causes chronic infections, See explains. The bacteria has components that mimic normal cellular components and are able to evade the immune system. They “trick” the immune system to leaving them alone and not attacking, as it would ordinarily do. This enables a chronic infection. Micoplasma incognitus can infect any tissues in the body, he adds. “We’ve found it in the brain, in joints, in the immune system, bone marrow, heart…any tissue. It settles in and causes significant dysfunction.” Then the immune system becomes dysfunctional because it is trying to fight an infection but cannot recognize it. This immune system dysfunction causes fatigue, headaches, and other symptoms related to where the bacteria has lodged. This bacteria, Dr. See further explains, is a cell walled deficient bacteria. Most bacteria have cell walls, which make them easy for the immune system to kill. Micoplasma incognitus have no cell wall. The good news is that if the patient with this bacteria is treated with antibiotics and certain supplements, the body can be rid of the organism. When it is eliminated, the patient improves dramatically, if not experiencing total cure according to Dr. See. He further explains the process. “The micoplasma does not begin the illness; it is a result of immune system dysfunction,” he says. “It finds a nice home and exacerbates symptoms. The current postulate is that the person (host) has defenses that are decreased against the microorganism. Then the microorganisms cause chronic infection, which begin the symptoms of CFS. Then starts the vicious cycle. The initial infection causes the immune system to be more suppressed, which allows other organisms to come in and cause infection.” Long-term antibiotics used to treat the bacteria are doxycycline, tetracycline, zithromax or any quinalone. Patients must be on the medications for at least three months, at which time they are re-tested for the presence of the incognitus bacteria. Dr. See notes that the micoplasma is hard to eradicate with antibiotics alone, and that nutritional supplementation while on the medications is especially important. “We always give pro-biotics with antibiotics,” he says. If all this treatment sounds expensive, it can be. Dr. See notes that although many insurance companies cover the cost of testing for the bacteria, supplementation is often at the patient’s expense. And not all laboratories are capable of performing these tests. See’s clinic offers a weeklong evaluation (roughly $2000) and many patients fly to Southern California specifically for it. For those who cannot visit, phone interviews are set up. See’s office determines which tests are necessary and specifies where to send the specimens for evaluation. Some patients who have undergone the treatment rave about their results. Mary O’Neill, a CFS sufferer and director of the Central California CFIDS Foundation, was tested and treated by one of See’s associates, Dr. Ferre Akbarpour. O’Neill’s symptoms, which included tender point pain, post exertional fatigue, malaise, cognitive deficits, and more are gone. “Now, unlike before, I can handle stress without getting sick.” She credits her recovery to the treatment she received. Because Chronic Fatigue Syndrome is as unique as each person who contracts it, each individual should consider his or her own situation and decide which treatment options seem to offer the best solution.  http://www.prohealth.com/library/showarticle.cfm?id=2873&t=CFIDS_FM